BPC-157
Body Protection Compound-157 · GEPPPGKPADDAGLV · ~1419 Da
Executive Summary
BPC-157 is a 15-amino-acid synthetic peptide that has been studied mainly in animals and cell models for tissue repair, gastrointestinal protection, and broader organ protection effects. The preclinical literature contains many positive findings across many models, but this is not the same thing as "clinically proven", and the mechanistic story is still incomplete. Human evidence is thin and low quality: a retrospective chart review of knee injections (uncontrolled, subjective outcomes), a small pilot study for interstitial cystitis (12 participants, no control group), and a two-person pilot safety study of IV infusion. A Phase I oral safety/PK study (NCT02637284) was registered but no results are posted in the public record. From a regulatory standpoint, BPC-157 is not an approved human medicine; it is prohibited in sport under the S0 category by WADA, and the U.S. FDA explicitly raises safety concerns around immunogenicity risk, peptide impurities, and lack of safety information.
BPC-157 is preclinical-promising but clinically unproven; most confident online claims are ahead of human evidence; and safety/quality risks are not solved by enthusiasm.
What BPC-157 Is and What It Is Not
BPC-157 is described in the literature as a stable gastric pentadecapeptide, typically written as the amino-acid sequence GEPPPGKPADDAGLV (molecular weight ~1419). It is repeatedly framed as originating from fragments identified in gastric juice research, and was developed in the context of gastrointestinal cytoprotection ideas (protecting mucosa and then extending that concept to other tissues).
- It is not an approved therapeutic drug for any indication by major regulators, and should not be written about as if it were a standard-of-care regenerative medicine.
- It is not supported by published randomised controlled trials (RCTs) in humans for common internet uses (tendon tears, muscle strains, gut repair, neuroprotection).
- It is not "clearly safe" in the way people casually claim, because publicly available human safety datasets are extremely small and regulators explicitly cite missing safety information plus manufacturing/characterisation concerns.
Mechanism of Action
Angiogenesis and endothelial/NO signalling
Clearest independent mechanistic supportA 2017 study reports pro-angiogenic effects associated with increased expression and internalisation of VEGFR2 and activation of VEGFR2-Akt-eNOS signalling, with angiogenesis assays and improved blood flow recovery in a rat hind-limb ischaemia model. A 2020 paper reports that BPC-157 modulates vasomotor tone in isolated aorta in a concentration- and nitric-oxide-dependent manner, and suggests NO generation via a Src-caveolin-1-eNOS pathway.
These pathways are plausible contributors to healing-adjacent biology (blood flow, endothelial function), but do not equal proven clinical repair in humans.
Tendon-cell and fibroblast biology
Suggestive, not dispositiveA cell study in tendon fibroblasts reports that BPC-157 up-regulates growth hormone receptor expression (dose- and time-dependent), and that growth hormone then increases proliferation signals with downstream JAK2 activation.
This belongs in a mechanistic leads box: it supports possible effects on cell proliferation signalling, but it is still several steps away from human tendon outcomes.
Anti-inflammatory and cytokine modulation
Demonstrated in animal models; human relevance unconfirmedMultiple animal studies report that BPC-157 modulates key pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6, with effects observed in colitis, adjuvant arthritis, and sepsis models. The peptide appears to attenuate excessive inflammatory signalling without complete immunosuppression, suggesting a modulatory rather than purely suppressive role.
Cytokine modulation in rodent inflammatory models is a real and documented effect, but it does not predict clinical anti-inflammatory efficacy in humans. Many compounds modulate cytokines in animals without translating to human therapeutics.
Cytoprotection and organoprotection
Broad preclinical signal; mechanism not fully resolvedBPC-157 has been studied in models of gastric, hepatic, cardiac, and renal injury, often framed around Robert's concept of adaptive cytoprotection — the idea that the GI tract can mount protective responses to sub-damaging stimuli. The peptide has shown protective effects against NSAID-induced gastric lesions, ethanol-induced damage, and ischaemia-reperfusion injury across multiple organ systems in rats.
The breadth of organ protection claims is itself a flag: a single peptide protecting every organ system equally would be extraordinary. The preclinical signal is real, but the leap from 'protects rat stomachs from aspirin' to 'heals organs in humans' is not supported by clinical evidence.
Nitric oxide system regulation
Consistent preclinical signal across multiple modelsMultiple studies suggest BPC-157 interacts with the nitric oxide (NO) system in a modulatory fashion — counteracting both NO-excess and NO-deficiency states in animal models. The peptide has been shown to activate eNOS via Src-caveolin-1-eNOS signalling, modulate vasomotor tone in isolated aorta preparations, and interact with L-NAME (NOS inhibitor) and L-arginine (NO precursor) pathways in fistula healing, blood pressure, and GI protection models.
NO system interaction is one of the more consistently reported mechanistic threads, but 'modulates NO' is not a clinical endpoint. How this translates to specific human therapeutic outcomes remains unknown.
Multiple proposed pathways
Claim, not resolved mechanismReviews describe interactions across neurotransmitters and the gut-brain axis, and repeatedly emphasise stability in gastric juice and broad system effects. These are hypothesis-generating narratives, not clinical proof, and they often synthesise many animal models without resolving bias, replication, or real-world dosing comparability.
BPC-157 has multiple proposed pathways (angiogenesis/NO, inflammatory signalling, cell migration), but "multiple pathways" can also mean "mechanism not pinned down yet."
A substantial proportion of the BPC-157 preclinical literature originates from one research group led by Predrag Sikirić at the University of Zagreb, Croatia. While prolific output from a single group is not inherently a flaw, it is a standard scientific concern: independent replication by other laboratories is limited, and the field would benefit from more diverse research groups reproducing key findings.
This does not invalidate the Zagreb group's work, but it means the literature base is less independently validated than it might appear from citation counts alone. Readers should weight this when evaluating the strength of evidence.
Animal Evidence Map
The preclinical literature contains many positive findings, summarised below with stated limitations.
| Domain | Species | Dose | Outcome | Limitation |
|---|---|---|---|---|
| Achilles tendon transection | Rat | Not detailed in early paper | Improved Achilles tendon healing and in-vitro tendocyte stimulation | Rodent tendon healing; does not establish effect size or reliability in human tendon pathology. |
| MCL transection | Rat | 10 ug/kg or 10 ng/kg i.p. daily; topical 1.0 ug/g cream; oral 0.16 ug/mL water | Multiple routes effective for ligament healing outcomes | Single species, surgically created injury, controlled environment; positive preclinical result does not inform human dosing, safety, or comparative effectiveness. |
| Quadriceps muscle transection | Rat | 10 ug/kg, 10 ng/kg, 10 pg/kg i.p. | Improved biomechanical load-to-failure, functional recovery, histological regeneration over 72 days | Dramatic results in rodents can be real and still fail to translate, especially when human injury types, rehabilitation forces, and comorbidities differ. |
| Colocutaneous fistula | Rat | 10 ug/kg or 10 ng/kg oral water or i.p. | Accelerated closure and improved functional leakage outcomes; NO-system interaction tested | Fistula models are far from the everyday leaky gut claim; repair in rats does not validate oral self-use or predict long-term human safety. |
| Neuroleptic gastric injury + catalepsy | Mouse/Rat | 10 ug/kg or 10 ng/kg i.p. | Attenuated neuroleptic-induced catalepsy and inhibited haloperidol-associated gastric lesions | These are pharmacology models; they support biological activity, not broad clinical claims like heals the gut lining in humans. |
| Systemic organ protection (I/R injury) | Rat | Standard research doses | Examined distant-organ injury (kidney/liver/lung) following skeletal muscle ischaemia-reperfusion | Systemic I/R models are complex; generalising them to human wellness claims is a major leap without controlled human clinical work. |
Human Evidence
Every published human study for BPC-157 is reviewed below. None are randomised controlled trials.
Retrospective knee pain injection study
Uncontrolled retrospective chart reviewSubjective outcomes, only minority had pre-procedure MRI, no randomisation, no control group, heterogeneous diagnoses, high risk of placebo effects and selection bias.
Hypothesis-generating at best. Cannot establish efficacy.Interstitial cystitis pilot
Single-site pilot, no control groupSmall sample, lack of sham control. The limitations section of the paper itself explicitly notes these issues.
Signal is interesting but this is not clinical validation; needs independent replication with blinded outcomes.IV infusion safety pilot
Pilot safety studyn=2 can only support a narrow statement. Cannot establish general safety, rare adverse events, long-term risks, or safety of non-IV routes.
No obvious acute toxicity in two people under those conditions. Not a safety database.Phase I oral safety/PK trial
Registered Phase I RCT (NCT02637284)A registered trial without public results is evidence of investigation, not evidence of efficacy or safety.
Evidence of investigation only. No posted results.Dosing & Administration in Research
No approved human dosing protocol exists for BPC-157 from any regulatory authority. The following summarises doses reported in published research. These are not recommendations.
Animal Study Doses
| Route | Dose | Context |
|---|---|---|
| Intraperitoneal (i.p.) | 10 µg/kg or 10 ng/kg body weight, daily | Most common dose range across rat studies (tendon, ligament, muscle, GI models) |
| Oral (drinking water) | 0.16 µg/mL in drinking water ad libitum | Used in rat ligament and fistula healing studies |
| Topical (cream) | 1.0 µg/g cream applied locally | Used in rat ligament healing studies |
Human Study Doses
| Route | Dose | Context |
|---|---|---|
| Intra-articular injection | 4 mg (2 cc of 2000 µg/mL) | Retrospective knee pain chart review (uncontrolled, 16 patients) |
| Intravesical injection | 10 mg total | IC pilot study (12 participants, no control group) |
| IV infusion | Up to 20 mg | Safety pilot (n=2 only) |
| Oral tablets | 1 mg per tablet (1–6 tablets per dose) | Registered Phase I trial (NCT02637284); no results posted |
- No regulatory body has established an approved dose for any indication.
- Animal-to-human dose extrapolation (e.g., allometric scaling) is unreliable for peptides with unknown human pharmacokinetics.
- The doses used in online self-administration communities often have no direct basis in published research.
- Route matters: bioavailability varies dramatically between i.p., oral, subcutaneous, and intra-articular administration, and human PK by route is not established.
Hype vs Evidence
Common online claims compared against what the published evidence actually supports.
| Claim | Social Media Implies | Evidence Supports | Verdict |
|---|---|---|---|
| Heals tendon tears / ligament ruptures fast | Direct repair of human tears; faster return to sport | Multiple rodent surgical injury models show improved healing at ng/kg-ug/kg dosing; human evidence limited to uncontrolled knee pain chart review (not tendon tears per se); registered hamstring strain trial exists but no outcomes yet. |
Preclinical-promising; clinically unproven
|
| Fixes knee pain and builds cartilage | Regenerates cartilage; avoids surgery | One uncontrolled retrospective injection study reports symptom improvement, but no control group, limited imaging, and subjective endpoints prevent efficacy conclusions. |
Not proven; high bias risk
|
| Heals the gut / leaky gut | Reliable human GI repair from oral dosing | Rat GI models (fistula healing, ulcer protection) show biological activity; human ulcerative colitis work referenced historically but public trial results not visible as full peer-reviewed clinical paper. |
Animal evidence exists; human proof missing
|
| Neuroprotective / dopamine / brain repair | Cognitive enhancement; treatment for neurological disease | Animal pharmacology signals exist (catalepsy attenuation; CNS-focused reviews), but there is no robust human neurological outcomes dataset. |
Speculative in humans
|
| Completely safe / no side effects | Safe enough for self-injection | Regulators explicitly cite insufficient safety information and immunogenicity/impurity concerns; human datasets are tiny (n=2 IV safety). |
Unsupported; safety is uncertain
|
| Legal and standard in clinics | Treated like routine peptide therapy | WADA prohibits; FDA flags compounding risk; anti-doping bodies warn of non-approved status and unknown dosing. |
Regulatory risk is real
|
Evidence Strength Ratings
Each domain rated on a 0-5 scale based on quality and quantity of available evidence.
Safety, Side Effects & Regulatory Status
Prototype BPC-157 showed short elimination half-life (<30 minutes) in rats and beagle dogs after IV and IM dosing, with rapid Tmax (~9 minutes) after IM injections; IM bioavailability ~14-19% in rats and ~45-51% in dogs. Using radiolabelled BPC-157, total radioactivity suggested extensive metabolism/decomposition; urinary excretion dominant, with higher levels later in kidney and liver. The "it's stable in the stomach so it must work orally" story is incomplete: stability and bioavailability are not the same, and animal PK does not substitute for human PK.
The human clinical literature is too small to establish safety: the knee pain chart review, the interstitial cystitis pilot, and the IV n=2 study are not a safety database. Animal studies and reviews often assert wide safety margins, but the highest-integrity approach is to anchor safety claims to actual regulatory statements.
BPC-157 is not registered as a pharmaceutical product with the Thai Food and Drug Administration (สำนักงานคณะกรรมการอาหารและยา / อย.). It is not listed in the Thai National List of Essential Medicines and has no approved therapeutic indication in Thailand. Peptide products available through Thai clinics and wellness providers operate in a regulatory grey area without standardised oversight for this specific compound.
View Official Source →BPC-157 was classified as a Category 2 bulk drug substance with cited safety risks (immunogenicity, impurities, insufficient safety data). In February 2026, U.S. HHS Secretary Kennedy announced that approximately 14 peptides including BPC-157 would be moved from Category 2 to Category 1 (eligible for compounding). As of late March 2026, this reclassification has not been formally completed by the FDA. Important: Category 1 compounding eligibility is not FDA approval, and U.S. regulatory developments have no bearing on Thai regulatory status.
View Official Source →In Thailand, peptides including BPC-157 are available through clinics, wellness providers, and online sellers with highly variable quality assurance. Without standardised regulatory oversight for this compound, there are no batch-release testing guarantees, no mandatory purity certificates, and no assurance of correct peptide identity or concentration. Contamination risk, sub-potency, and misidentification are real concerns when sourcing from unregulated suppliers.
View Official Source →Named as an example under S0 on the 2026 Prohibited List (valid 1 January 2026). Added by name in 2022 after re-evaluation.
View Official Source →Emphasises BPC-157 is prohibited and not approved for human clinical use; safe dosing is unknown because it has not been extensively studied in humans.
View Official Source →Describes BPC-157 as an unapproved drug; safety/effectiveness have not been thoroughly evaluated in humans.
View Official Source →What We Still Don't Know
- No published human RCTs for tendon/ligament/muscle healing outcomes.
- No robust human pharmacokinetics by route (oral vs subcutaneous vs intra-articular), and animal PK does not solve this.
- No credible long-term safety database; rare harms cannot be ruled out from n=2 or n=12 studies.
- No manufacturing-quality reassurance in grey markets; FDA explicitly flags peptide impurity/characterisation complexities and limited safety information.
- Mechanism remains incomplete: endothelial/angiogenic signalling is plausible, but a unifying target that predicts who benefits, who doesn't, and who is harmed is not established.
- Most preclinical BPC-157 studies originate from a single research group (University of Zagreb); independent replication by other laboratories is limited.
References
All primary sources cited in this review. Links open in new tabs.
-
BPC-157 Achilles tendon transection healingEarly paper describing improved Achilles tendon healing and in-vitro tendocyte stimulation in rats
-
MCL transection ligament healing with multiple routesRat MCL healing with i.p., topical, and oral administration routes
-
Colocutaneous fistula healing with NO-system interactionRat fistula closure with BPC-157 at 10 ug/kg and 10 ng/kg; NO-system interaction tested
-
Quadriceps transection healing across dose rangesRat muscle healing at 10 ug/kg, 10 ng/kg, 10 pg/kg i.p. over 72 days
-
Neuroleptic catalepsy attenuation and gastric ulcer protectionBPC-157 attenuated neuroleptic-induced catalepsy and inhibited haloperidol-associated gastric lesions in mice/rats
-
Growth hormone receptor up-regulation in tendon fibroblastsCell study showing BPC-157 up-regulates GHR expression with downstream JAK2 activation
-
Pro-angiogenic mechanism via VEGFR2-Akt-eNOS pathwayDemonstrated VEGFR2-Akt-eNOS signalling and improved blood flow recovery in rat hind-limb ischaemia
-
Vasomotor tone and Src-Cav-1-eNOS signallingBPC-157 modulates vasomotor tone in isolated aorta via Src-caveolin-1-eNOS pathway
-
PK/ADME in rats and dogsPharmacokinetics, biodistribution, and metabolism study including radiolabel distribution and IM bioavailability
-
Intra-articular injection for multiple types of knee painRetrospective chart review of 16 patients with intra-articular BPC-157 injections
-
Intravesical BPC-157 for interstitial cystitis pilotPilot study of 12 women with IC; intravesical injection totaling 10 mg
-
IV infusion safety pilot (n=2)IV infusion up to 20 mg in 2 healthy adults; no adverse effects reported
-
Phase I oral safety/PK trial (NCT02637284)Registered Phase I RCT for oral BPC-157 tablets; unknown status, no posted results
-
Systematic review: orthopaedic sports medicine perspectiveSystematic review noting limited clinical evidence for BPC-157 in orthopaedic applications
-
Anti-inflammatory effects and cytokine modulationBPC-157 modulates TNF-α, IL-1β, and IL-6 in inflammatory models including colitis and adjuvant arthritis in rats
-
Cytoprotective and organoprotective effectsReview of BPC-157 cytoprotection across gastric, hepatic, and multi-organ injury models in rats, framed within Robert's cytoprotection concept
View the compound profile for BPC-157 including dosage forms, administration routes, and category information.
View Compound Profile →Frequently Asked Questions About BPC-157
BPC-157 shows promising results in animal studies for tissue repair, gastrointestinal protection, and organ protection. However, human clinical evidence is extremely limited. No published randomised controlled trials exist for common claims like tendon repair, gut healing, or neuroprotection. The overall evidence score is 2.5 out of 5.
Safety is uncertain. The human safety database is extremely small (studies with only 2–16 participants). The U.S. FDA explicitly cites potential safety risks including immunogenicity concerns and peptide impurities. It is prohibited in sport by WADA under the S0 category.
Due to the very small number of human studies, a comprehensive side effect profile has not been established. The limited studies report no obvious acute toxicity, but regulatory agencies warn about immunogenicity risk, peptide-related impurities, and insufficient safety information to determine whether it would cause harm.
Multiple rodent studies show improved tendon and ligament healing outcomes. However, human evidence is limited to one uncontrolled retrospective chart review of knee injections (16 patients, no control group). No published human RCTs exist for tendon or ligament healing.
BPC-157 is not a registered pharmaceutical in Thailand (อย.) and is not an approved human medicine by any major regulator internationally. It is prohibited in sport by WADA under S0 (Non-Approved Substances). In the U.S., it was classified as a Category 2 bulk drug substance; a reclassification was announced in February 2026 but has not been formally completed. In Thailand, peptide products are available through clinics and online sellers but operate in a regulatory grey area.
Rat gastrointestinal models show biological activity for fistula healing and ulcer protection. However, human clinical proof of gut healing is missing. No peer-reviewed clinical trial results demonstrate GI repair efficacy in humans from oral dosing.
The clearest mechanistic evidence involves pro-angiogenic effects through VEGFR2-Akt-eNOS signalling, promoting blood vessel formation and blood flow. Additional proposed pathways include tendon fibroblast stimulation, anti-inflammatory cytokine modulation (TNF-α, IL-1β, IL-6), cytoprotection of organ tissues, and nitric oxide system regulation. However, a unifying mechanism is not yet established, and 'multiple pathways' can also mean the mechanism has not been pinned down.
A substantial proportion of BPC-157 preclinical research originates from one laboratory group led by Predrag Sikirić at the University of Zagreb, Croatia. While their work is extensive and widely cited, independent replication by other research groups is limited. This is a standard scientific concern — not an invalidation of the work, but a reason to interpret the overall evidence base with appropriate caution.
Animal studies typically use 10 µg/kg or 10 ng/kg body weight (intraperitoneal injection in rats). The few human studies used much higher absolute doses: 4 mg intra-articular (knee), 10 mg intravesical (bladder), and up to 20 mg IV (safety pilot with 2 people). No approved human dosing protocol exists, and animal-to-human dose extrapolation is unreliable for peptides with unknown human pharmacokinetics.
Have Questions About BPC-157?
Connect with a peptide specialist to discuss BPC-157 research, protocols, and evidence-based information.
Connect with a SpecialistReviewed by the Peptide Science Thailand Editorial Team.
Last reviewed: March 1, 2026